Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

And while I expected emraclidine to be one of the more important growth drivers for AbbVie's neuroscience pipeline in the ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

Cutia Therapeutics’ CEO, Ms. Zhang Lele, has further increased her stake in the company by purchasing an additional 5,000 ...

The centerpiece drug of AbbVie’s $9 billion acquisition of Cerevel Therapeutics has failed in two Phase II ... failure ...

Their presence underscored the event’s prominence and highlighted the profound influence of cross-national business ...